The new Gyrolab™ Generic PK Kit is optimized for use in automated, nanoliter-scale Gyrolab xP and Gyrolab xPlore™ systems, enabling quantification of human therapeutic antibodies. The kit is designed for use with several species of preclinical animal models, including mouse and cynomolgus monkey. While most other immunoassays for PK applications can take up to a full day to get results, the new Gyrolab Generic PK Kit saves the researcher a significant amount of time as pharmacokinetic results are generated in just one hour.

This generic kit for human therapeutic antibodies reduces the need for researchers to develop assays using costly analyte specific reagents. As the kit is supplied in an optimized, ready-to-use format, it also reduces the need for assay development, saving scientists’ time. The broad dynamic range of the kit minimizes the need for dilutions and repeats, which can introduce errors, supporting the needs of researchers to deliver high quality results. Moreover, Gyrolab assays consume nanoliter volumes, providing major preclinical benefits by enabling serial sampling of fewer mice to generate better data for more analyses while using less material.

Jasmine Gruia-Gray, VP Marketing, Gyros Protein Technologies, commented: “Part of Gyros Protein Technologies’ mission is to ensure that Gyrolab systems are recognized in the biotherapeutics industry as the gold standard for immunoassays in time-critical workflows. The new Gyrolab Generic PK Kit maximizes productivity while minimizing errors, and saving researchers’ time.”

Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing